Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Allergan – Title: A Multi-Center, Investigator Masked, Randomized, Parallel Group Comparison Study to Assess if the Presence of Benzalkonium Chloride (BAK) in a Topical Fluoroquinolone Reduces the Likelihood of Susceptibility for Induction of Resistant Organisms in Healthy Adult Subjects MA-ZYM-08-001 Objective: To evaluate for the development of resistant ocular isolates following topical use of Zymar and Vigamox. Emmes – Title: Age-Related Eye Disease Study 2 (AREDS2: A Multi-Center, Randomized Trial of Lutein, Zeanthin, and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in Age-Related Macular Degeneration Objective: The purpose of this study is to help the doctors learn if certain vitamins or minerals, and /or dietary supplements, can help to stop or slow down AMD. The study will also look at if stopping or decreasing certain vitamins or minerals helped slow down AMD. National Eye Institute – Title: Infant Aphakia Treatment Study (IATS) Objectives: To determine whether infants with a unilateral congenital cataract are more likely to develop better vision following cataract surgery, have postoperative complications, and experience less stress if they 1) undergo the primary implantation of a lens or if 2) they are treated primarily with a contact lens. . Title: Antioxidant Systems and Age-Related Macular Degeneration Objective: The purpose of this study is to find out if there are changes in blood that would make you at risk for having age related macular degeneration. The study will help us learn if your blood has signs of oxidative stress (cell damage). The cell damage is a sign of AMD. Othera Pharmaceuticals, Inc., - Title: OT-551-C04- A Randomized, Double-masked, Dose-ranging, Multi-center, Phase II Study Comparing the Safety and Efficacy of OT-551 with the Placebo to Treat Geographic Atrophy Associated with Age-related Macular Degeneration Objective: The purpose of this study is to find out if an investigational drug called OT-551 is safe and effective in helping people with macular degeneration to slow down any further progression of AMD. Investigational means the drug is not approved by the Food and Drug Association (FDA). OT-551 will be given to you as an eye drop in this study. Title: Investigation of Cornea-derived Transcript 6 (CDT6) as a Candidate Gene for Adult-onset Primary Open-angle Glaucoma (POAG) Objective: The purpose of this study is to help us learn if we can identify genes that can be linked to glaucoma. If the doctors can identify a genetic cause of glaucoma it may lead to improvement in evaluation and treatment options for patients. Title: Investigation of Cornea-derived Transcript 6 (CDT6) as a Candidate Gene for Primary Congenital Glaucoma Objective: The purpose of this study is to help us learn if we can identify genes that can be linked to glaucoma. If the doctors can identify a gentetic cause of glaucoma it may lead to improvement in evaluation and treatment options for patients. JAEB Center - Title: Nasolacrimal Duct Obstruction Study 3 (NLD3) A Randomized Trial Comparing Immediate Probing in an Office Setting with Deferred Probing in a Facility Setting for Treatment of Nasolacrimal Duct Obstruction in Children 6 to < 10 months old Objective: The primary objective of this study is to determine the cost-effectiveness of treating NLDO using immediate office probing compared with deferred probing in a facility setting. As part of the primary objective, the study will determine the proportion of eyes experiencing spontaneous resolution among subjects randomized to the deferred probing group. JAEB Center -Title: Amblyopia Treatment Study (ATS14) A Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia in 8 to 17 Year Olds Objective: The study is a single treatment pilot study designed to evaluate levodopa as adjuctive treatment to patching for residual amblyopia (20/50 or worse) in older children and teenagers ages 8 to 17 years old. Subjects will be treated with 2 hours of daily patching plus oral administration of a combination of levodopa and carbidopa for 7 weeks. Title: Wavefront Guided Refraction and Prescription of Spectacle Lenses Objective: The purpose of this study is to determine if patients who have had LASIK or penetrating Keratoplasty will have better vision with iZon spectacle lenses instead of traditional spectacle lenses. Title: PIRATE: Preoperative Intravitreal Ranibizumab as Adjunctive Treatment for Diabetic Retinopathy Objective: The purpose of the study is to help us learn if the study drug (Lucentis) is safe and works well when injected into the vitreous before surgery. The study drug is investigational in this study, which means it is not FDA approved for this use. We want to find out if it will help decrease the swelling in the back of the eye Title: Project PAVE: Providing Access to the Visual Environment Objective: The purpose of this study is to help children and teenagers with low vision find out if optical devices (magnifiers, small telescopes, or other lenses) can help them to see books, the chalkboard, and other objects. Allergan - Title: PROOF A Multi-Center, Prospective, Observational Study of the Progression Of Ocular Findings in Patients with Dry Eye Disease (MA-RES-08-001) Objective: The purpose of this study is to develop a better understanding of the natural history of dry eye. Title: Illuminated Low Vision Glasses Trial (ILVG) Objective: The purpose of this study is to determine if patients who have vision impairment can read smaller letters using glasses with lights built into the frame. This study is being done to find out how well the glasses work before being sold to the public. Allergan – Title: AKC A Multicenter, Randomized, Double-Masked, Parallel-Group Study Evaluating the Efficacy and Safety of Cyclosporine Ophthalmic Solution 0.010% Compared with its Vehicle Administered QID for 3 Months Followed by a 9 Month Open-Label Phase in Patients with Atopic Keratoconjunctivitis Objective: The purpose of this study is to help us learn if using a certain eye drop will help with the treatment of AKC. Allergan – Title: BEG A One Year, Multicenter, Double-Masked, Randomized, Parallel-Group Study Assessing the Safety and Efficacy of Once Daily Application of Bimatoprost 0.03% Solution Compared to Vehicle to Treat Hypotrichosis of the Eyelashes from Varied Etiologies Objective: The purpose of this study is to learn about the long-term safety and effectiveness of the study drug, bimatoprost 0.03% solution, in the treatment of hypotrichosis (decrease of eyelash growth) of the eyelashes due to natural causes or related to recent chemotherapy treatment. Diabetic Clinical Research Center Network – Title: DRCR protocol L Evaluation of the Reproducibility of Electronic-ETDRS Measurements in Eyes with Diabetic Macular Edema Objective: The purpose of this study is to check the accuracy of a vision testing method in patients with diabetic macular edema. Intramural Studies Department: Multiple Sclerosis Clinic Novartis Study - Title: Fingolimud (FTY720) A 24-month double-blind, randomized, multicenter, placebo-controlled, parallelgroup study comparing the efficacy and safety of 0.5mg and 1.25mg administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis Objective: To compare fingolimod 1.25mg and 0.5mg with placebo to demonstrate that at lest 1.25mg is superior to placebo in terms of annualized relapse rate for patients with RRMS treated for up to 24 months. Department: Gastroenterology, Hepatology and Nutrition Title: ELEVATE Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures. ELEVATE: ELtrombopag EValuated for its Ability to overcome Thrombocytopenia and Enable procedures Objective: To demonstrate the ability of eltrombopag, compared to placebo to reduce the proportion of subjects with chronic liver disease and thrombocytopenia who receive platelet transfusions administered prior to, during and up to seven days following elective invasive procedures. Department: Gastroenterology, Hepatology and Nutrition Title: ENABLE 1 Randomized, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C viris (HCV) infection who are otherwise eligible to initiate antiviral thereapy (peginterferon alfa-2a plus ribavirin) ENABLE 1: Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseaseE Department: Gastroenterology, Hepatology and Nutrition Title: ENABLE 2 Randomized, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C viris (HCV) infection who are otherwise eligible to initiate antiviral thereapy (peginterferon alfa-2b plus ribavirin) ENABLE 2: Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseaseE Title: GI 0701 A Phase II, Open Label, Multiple Center Study of huC242-DM4 Given as an Intravenous Infusion Once Every Three Weeks to Patients with Metastatic Gastric or Gastroesophageal Junction Carcinomas Objective: To assess the objective response rate of huC242-DM4 given as a single intravenous infusion at 126mg/m2 once every three weeks to patients who have metastatic gastric and gastroesophageal junction cancer and have low plasma CanAg levels (<1000 U/m1). An exploratory assessment of response rate in patients with high CanAg levels (> 1000U/ml) treated with huC242-DM4 given as a single intravenous infusion at 168mg/m2 once every three weeks will also be performed. Title: EDIC Epidemiology of Diabetes Interventions and Complications